HLS Therapeutics Inc (HLS : TSX)
Common Stock
Follow HLS
HLS
HLS Therapeutics Inc
Performance
1 Day
+1.08%
1 Week
-14.19%
1 Month
-8.54%
YTD
-22.68%
The Saturday TSX Wrap · free, every saturday morning. The week on the TSX, in five minutes.
Key Statistics
Market Cap
$129.62M
52W High
$5.25
52W Low
$3.56
P/E Ratio
-
50 Day MA
$4.09
200 Day MA
$4.30
Beta
0.71
Dividend Yield
-
WA Score
How HLS stacks up against 944 Canadian stocks
out of 99
- Value23
Not profitable over the last 12 months.
- Quality
- Momentum32
−22.7% this year, below its 200-day average, 11% of the way up its 52-week range.
- Analysts
- Insiders
Each factor is a percentile against Canadian common stocks worth $50M or more on the TSX and TSX Venture (90 = better than 90% of them). Built from exchange prices, company financials, analyst targets and SEDI insider filings. A data summary, not advice. How it works · Top-scoring stocks
Performance history
HLS returns since 2023
HLS Therapeutics Inc has traded since Nov 2023 in our data, with 1 up year out of 2 full calendar years. Its deepest fall was −41.8% (Apr 2024 to Aug 2024).
1 year / yr
−23.5%
3 years / yr
+1.8%
5 years / yr
—
10 years / yr
—
Calendar-year returns
- 2023*−9.2%
- 2024−0.5%
- 2025+22.6%
- 2026*−22.2%
* Partial year (first year of data, or year to date).
$10,000 invested in HLS
- 1 year ago$7,653
- 2023 (start of our data)$8,621
- Best year
- 2025: +22.6%
- Worst year
- 2024: −0.5%
- All-time high in our data
- $6 on Sep 9, 2025 · now −33.6%
Total-return basis using adjusted daily closes from the Toronto Stock Exchange and TSX Venture (dividends and splits folded in), Nov 2023 to Nov 2026. Past returns do not predict future ones.
Earnings
HLS earnings history
HLS Therapeutics Inc beat the EPS estimate in 3 of its last 4 reported quarters.
| Quarter ending | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 30, 2026 | Nov 12, 2026 | −$0.07 | −$0.08 | +12.5% |
| Jun 30, 2026 | Aug 12, 2026 | −$0.03 | −$0.08 | +62.5% |
| Mar 31, 2026 | May 6, 2026 | −$0.07 | −$0.12 | +41.7% |
| Dec 31, 2025 | Mar 12, 2026 | −$0.04 | −$0.03 | −33.3% |
| Sep 30, 2025 | Nov 13, 2025 | −$0.12 | −$0.07 | −71.4% |
| Jun 30, 2025 | Aug 14, 2025 | −$0.09 | −$0.08 | −12.5% |
| Mar 31, 2025 | May 8, 2025 | −$0.14 | −$0.17 | +17.6% |
| Dec 31, 2024 | Mar 13, 2025 | −$0.10 | −$0.09 | −11.1% |
EPS as reported vs consensus estimate. TSX earnings calendar →
Awesome Portfolio™
Looking past HLS? Our 10 best Canadian stocks, in one list.
14.8% a year since 2017 against 9.7% for the S&P/TSX Composite (+5.0 points a year). Reviewed every month.
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 11/16/2026 | $3.83 | $3.90 | $3.74 | $3.75 | $3.75 | 62,811 |
| 11/13/2026 | $3.70 | $3.73 | $3.51 | $3.71 | $3.71 | 172,776 |
| 11/12/2026 | $4.14 | $4.14 | $3.70 | $3.70 | $3.70 | 89,830 |
| 11/11/2026 | $4.40 | $4.40 | $4.10 | $4.19 | $4.19 | 37,125 |
| 11/10/2026 | $4.37 | $4.37 | $4.13 | $4.15 | $4.15 | 33,069 |
| 11/9/2026 | $4.50 | $4.50 | $4.34 | $4.37 | $4.37 | 14,865 |
| 11/6/2026 | $4.46 | $4.48 | $4.39 | $4.41 | $4.41 | 11,354 |
| 11/5/2026 | $4.49 | $4.50 | $4.26 | $4.44 | $4.44 | 56,190 |
| 11/4/2026 | $4.49 | $4.49 | $4.22 | $4.25 | $4.25 | 39,598 |
| 11/3/2026 | $4.48 | $4.69 | $4.20 | $4.23 | $4.23 | 56,604 |
Analyst Price Targets
Based on analyst covering HLS · as of Nov 12, 2026
Wall Street analysts forecast HLS stock price to rise 100.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.51
+100.3% Upside
Previously C$7.48 on Nov 11, 2026
Current Price
C$3.75
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HLS's historical volatility
30-Day Vol
55.7%
Annualized
90-Day Vol
44.9%
Annualized
Trend (90d)
-20.8%
Annualized drift
90d Mean
C$3.48
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$3.66 | C$3.02 – C$4.43 |
| 60 trading days | C$3.57 | C$2.72 – C$4.68 |
| 90 trading days | C$3.48 | C$2.50 – C$4.86 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About HLS Therapeutics Inc
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances and simplifies the mandatory safety blood monitoring process for patients that are prescribed Clozaril; Nilemdo, a bempedoic acid product for cardiovascular risk reduction; Nexlizet, a bempedoic acid and ezetimibe product for cardiovascular risk reduction; and Vascepa, an icosapent ethyl capsule for the treatment of cardiovascular disease. It also distributes MyCare psychiatry lab assays, which are a line of tests that can be processed on analyzers used in laboratory systems to measure the blood levels of the most common antipsychotic drugs, including clozapine, risperidone, quetiapine, aripiprazole, olanzapine, and paliperidone; and MyCare Insite, a point-of-care device that requires only a single drop of blood taken by a finger stick to measure patient drug levels. In addition, the company holds royalty interest in Takeda's Obizur, a porcine recombinant Factor VIII for acquired Hemophilia A. It serves wholesalers and institutions. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.
Financials
- Revenue (TTM)
- $56.24M
- EBITDA
- $17.01M
- Profit Margin
- -15.24%
- ROE (TTM)
- -14.07%
- EPS (Diluted)
- -0.37
- Book Value
- 2.48
Classification
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Free newsletter
The Saturday TSX Wrap
The week on the TSX, in five minutes
- The biggest gainers and losers, and why they moved
- Sector and momentum moves at a glance
- The Canadian market stories you missed
Explore More
Common Questions About HLS
Market movers
Recent TSX movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| HWO | High Arctic Energy Services Inc. | $1.74 | +29.85% |
| AAV | Advantage Oil & Gas Ltd. | $13.45 | +23.74% |
| LUC | Lucara Diamond Corp | $0.13 | +13.64% |
| T | Telus Corp | $13.70 | +12.85% |
| FRX | Fennec Pharmaceuticals Inc | $18.35 | +10.81% |
| KEL | Kelt Exploration Ltd. | $12.72 | +10.70% |
| NVO | Novo Resources Corp | $0.07 | +8.33% |
| ELO | Eloro Resources Ltd. | $1.23 | +7.89% |
Free with a Wealth Awesome account
Keep analysing HLS, free
- Every WA Score, ranking and table
- Insider track records and SEDI filings
- Earnings history and analyst targets for every stock
Email only, no password, no card. Already a member? Use the same button to sign in.